drugset

drugset / Trial / NCT05361447

Diazepam Trial in GAD65 Associated Epilepsy

NCT05361447 ↗

Phase 1/2 Withdrawn Mayo Clinic

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether diazepam reduces the frequency of seizures in GAD65 antibody associated epilepsy.

Timeline

Start: 2023-01-11
Primary completion: 2024-12-13
Completion: 2024-12-13

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Diazepam	Small molecule	10 mg	Oral

Indications